Summary
This internally produced session will use some not-so hypothetical situations and take attendees through the important disclosure decisions at the IPO stage and thereafter. Securities Litigation partners Deborah Birnbach and Adam Slutsky, and Life Sciences partner Larry Wittenberg, will focus on managing risk through important and typical stages life sciences companies face in their interaction with FDA, such as risk arising from FDA comments and guidance, predicting the timing and completion of clinical trials and expressing optimism regarding FDA approval.
Speakers
- /en/people/b/birnbach-deborah
Deborah S. Birnbach
PartnerCo-Chair, Public M&A / Corporate Governance - /en/people/s/slutsky-adam
Adam Slutsky
Partner - /en/people/w/wittenberg-lawrence
Lawrence S. Wittenberg
Of Counsel